MedPath
HSA Approval

ROBITUSSIN PS SYRUP

SIN12223P

ROBITUSSIN PS SYRUP

ROBITUSSIN PS SYRUP

March 7, 2003

GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.
Licence HolderGSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CA10

combinations

Manufacturer Information

gsk consumer healthcare singapore pte. ltd.

INTERPHIL LABORATORIES INC

Active Ingredients

PSEUDOEPHEDRINE HCl

60 mg/10 ml

Pseudoephedrine

GUAIPHENESIN

200 mg/10 ml

Guaifenesin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.